-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to incomplete statistics in the industry, from February 1st to February 21st, the enthusiasm of institutional research was still high.
Fund companies, securities companies, QFII and other institutions gathered together to investigate more than 280 A-share listed companies
.
Among them, the fund company investigated 218 A-share listed companies.
From the industry perspective, they mainly focus on electronics, computers, medicine and biology and other fields
.
As far as the field of medicine and biology is concerned, 3 pharmaceutical companies received more than 30 fund companies within the month, namely Huadong Medicine (42), Mindray Medical (39), and Changchun High-tech (38)
.
Among them, according to the "Record Form of Investor Relations Activities on February 9, 2022" released by Huadong Medicine on February 10, on February 9 this year, the company received GF Fund, Wells Fargo Fund, Southern Asset Management, Harvest Fund and other institutions and 336 individual investors
.
In the investor interaction session, the agency mainly focused on the sales and promotion of the company's Reaction™ products in the domestic market, the company's follow-up M&A strategy for the company's medical and aesthetic business, and the company's current integration with Spain's High Tech
.
Among them, in terms of the M&A strategy of the medical beauty business, the company replied that: the company has an international medical beauty BD project team, and the British wholly-owned subsidiary Sinclair is used as the international operation platform of the company's medical beauty business, and has certain business development in overseas projects.
advantage
.
In the future, we will actively look for innovative, world-class, high-tech medical and aesthetic targets, actively negotiate projects that meet the company's business development plan, and continue to progress steadily in accordance with the established "global operation layout, dual-cycle operation and development" strategy
.
Mindray Medical's investor relations activity record sheet disclosed on February 11 shows that from January 18th to January 21st, January 24th to January 27th, and February 10th, there were a total of 263 people from 201 institutions in the research activities.
participants
.
In this employee stock ownership plan, the company has formulated an assessment indicator for a 20% increase in profit in the next three years, and the agency has paid attention to the company's confidence in achieving this performance goal..
Mindray Medical said that from the perspective of the company's business, it is expected that the company will mainly have the following four sources of growth in the next three years, including: the new medical infrastructure on a global scale in the post-epidemic era is imperative, and the company has a complete product line and mature.
Sanrui IT solutions, as well as cost-effective attributes and overall solutions; the company's share in the international market is still very low, and there is still a lot of room for improvement; IVD will become an important source of growth for the company in the future; animals The four seed businesses of medical treatment, minimally invasive surgery, orthopedics, and AED are expected to maintain rapid development in the next three years
.
The record form of investor relations activities disclosed by Changchun Hi-Tech on February 21 shows that 145 institutional investors including Broadway Fund and Bosera Fund investigated the company on February 18.
Issues such as the layout of new products have attracted institutional attention
.
In addition, the Guangdong Provincial Drug Trading Center recently issued the "Notice on Launching the Registration Work for the Centralized Procurement of Chinese Patent Medicines such as Qingkailing in Guangdong Alliance"
.
The alliance members include Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai and other 6 provinces, involving 132 centralized procurement products
.
In this survey, the agency also raised the relevant issues of the Guangdong Centralized Procurement Alliance.
Changchun High-tech responded that on the deadline for the registration of the Guangdong Centralized Procurement Alliance, Jinsai Pharmaceuticals declared three powder specifications, but the water preparation has not been declared
.
The company will actively participate in the centralized procurement, while taking into account the interests of the company and shareholders in accordance with laws and regulations
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Fund companies, securities companies, QFII and other institutions gathered together to investigate more than 280 A-share listed companies
.
Among them, the fund company investigated 218 A-share listed companies.
From the industry perspective, they mainly focus on electronics, computers, medicine and biology and other fields
.
As far as the field of medicine and biology is concerned, 3 pharmaceutical companies received more than 30 fund companies within the month, namely Huadong Medicine (42), Mindray Medical (39), and Changchun High-tech (38)
.
Among them, according to the "Record Form of Investor Relations Activities on February 9, 2022" released by Huadong Medicine on February 10, on February 9 this year, the company received GF Fund, Wells Fargo Fund, Southern Asset Management, Harvest Fund and other institutions and 336 individual investors
.
In the investor interaction session, the agency mainly focused on the sales and promotion of the company's Reaction™ products in the domestic market, the company's follow-up M&A strategy for the company's medical and aesthetic business, and the company's current integration with Spain's High Tech
.
Among them, in terms of the M&A strategy of the medical beauty business, the company replied that: the company has an international medical beauty BD project team, and the British wholly-owned subsidiary Sinclair is used as the international operation platform of the company's medical beauty business, and has certain business development in overseas projects.
advantage
.
In the future, we will actively look for innovative, world-class, high-tech medical and aesthetic targets, actively negotiate projects that meet the company's business development plan, and continue to progress steadily in accordance with the established "global operation layout, dual-cycle operation and development" strategy
.
Mindray Medical's investor relations activity record sheet disclosed on February 11 shows that from January 18th to January 21st, January 24th to January 27th, and February 10th, there were a total of 263 people from 201 institutions in the research activities.
participants
.
In this employee stock ownership plan, the company has formulated an assessment indicator for a 20% increase in profit in the next three years, and the agency has paid attention to the company's confidence in achieving this performance goal..
Mindray Medical said that from the perspective of the company's business, it is expected that the company will mainly have the following four sources of growth in the next three years, including: the new medical infrastructure on a global scale in the post-epidemic era is imperative, and the company has a complete product line and mature.
Sanrui IT solutions, as well as cost-effective attributes and overall solutions; the company's share in the international market is still very low, and there is still a lot of room for improvement; IVD will become an important source of growth for the company in the future; animals The four seed businesses of medical treatment, minimally invasive surgery, orthopedics, and AED are expected to maintain rapid development in the next three years
.
The record form of investor relations activities disclosed by Changchun Hi-Tech on February 21 shows that 145 institutional investors including Broadway Fund and Bosera Fund investigated the company on February 18.
Issues such as the layout of new products have attracted institutional attention
.
In addition, the Guangdong Provincial Drug Trading Center recently issued the "Notice on Launching the Registration Work for the Centralized Procurement of Chinese Patent Medicines such as Qingkailing in Guangdong Alliance"
.
The alliance members include Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai and other 6 provinces, involving 132 centralized procurement products
.
In this survey, the agency also raised the relevant issues of the Guangdong Centralized Procurement Alliance.
Changchun High-tech responded that on the deadline for the registration of the Guangdong Centralized Procurement Alliance, Jinsai Pharmaceuticals declared three powder specifications, but the water preparation has not been declared
.
The company will actively participate in the centralized procurement, while taking into account the interests of the company and shareholders in accordance with laws and regulations
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
